Results 211 to 220 of about 9,412 (255)
Some of the next articles are maybe not open access.
Research Journal of Science and Technology, 2021
The purpose of the present study was to prepare, characterize and evaluate the colon-targeted microspheres of mesalamine for the treatment and management of ulcerative colitis (UC).
Deepa H. Patel, S. Shah, C. Tyagi
semanticscholar +1 more source
The purpose of the present study was to prepare, characterize and evaluate the colon-targeted microspheres of mesalamine for the treatment and management of ulcerative colitis (UC).
Deepa H. Patel, S. Shah, C. Tyagi
semanticscholar +1 more source
Multicenter survey on mesalamine intolerance in patients with ulcerative colitis
Journal of Gastroenterology and Hepatology, 2020Although oral mesalamine is the first‐choice drug for treating mild‐to‐moderate ulcerative colitis (UC), some patients show symptoms of intolerance, including exacerbation of diarrhea and abdominal pain.
S. Hiraoka +12 more
semanticscholar +1 more source
Designing a biocompatible hydrogel for the delivery of mesalamine
International Journal of Pharmaceutics, 2015A new design for nanocomposite hydrogels based on cross-linked chitosan for the delivery of mesalamine is presented. To enhance drug loading in chitosan, the mineral montmorillonite was incorporated into the matrix. The exfoliated silica montmorillonite nanosheets form interactions with both chitosan and mesalamine, which affect the hydrogel's drug ...
Havazelet Bianco-Peled, Lena Neufeld
openaire +2 more sources
Effectiveness of mesalamine and propolis in experimental colitis
Advances in Therapy, 2007This study was conducted to investigate the effects of propolis and mesalamine on experimental colitis in rats. Distal colitis was induced in rats by intracolonic instillation of 2 mL of 4% acetic acid. The animals were randomly assigned to 5 groups: group 1, control, (n=8); group 2, colitis, received no treatment (n=8); group 3, colitis+mesalamine, 2 ...
Esin Atik +7 more
openaire +3 more sources
American Journal of Gastroenterology, 2014
Poor adherence to mesalamine is common and driven by a combination of lifestyle and behavioral factors, as well as health beliefs. We sought to develop a valid tool to identify barriers to patient adherence and predict those at risk for future nonadherence.A 10-item survey was developed from patient-reported barriers to adherence.
Gary L. Horowitz +7 more
openaire +3 more sources
Poor adherence to mesalamine is common and driven by a combination of lifestyle and behavioral factors, as well as health beliefs. We sought to develop a valid tool to identify barriers to patient adherence and predict those at risk for future nonadherence.A 10-item survey was developed from patient-reported barriers to adherence.
Gary L. Horowitz +7 more
openaire +3 more sources
Mesalamine-Induced Lung Disease
Archives of Internal Medicine, 1997Mesalamine (5-aminosalicylic acid), which is a component of sulfasalazine, has been used to treat inflammatory bowel diseases.1Most adverse pulmonary symptoms caused by treatment with sulfasalazine have been attributed to sulfapyridine.2Therefore, we thought it would be of interest to your readers to report a case involving an adverse pulmonary ...
M. T. Lázaro +2 more
openaire +2 more sources
Mesalamine derivatives in the treatment of Crohn's disease
Gastroenterology Clinics of North America, 2004The role of the aminosalicylates for induction therapy of mild moderate ulcerative colitis and as maintenance treatment has been substantiated by a large series of controlled clinical trials and confirmatory meta-analyses. Both sulfasalazine and newer derivatives are effective in preventing relapses.
Laura Harrell, Stephen B. Hanauer
openaire +3 more sources
Journal of Drug Delivery Science and Technology, 2023
Mayank Kumar Malik +3 more
semanticscholar +1 more source
Mayank Kumar Malik +3 more
semanticscholar +1 more source